Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07214727
PHASE1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Sponsor: Alnylam Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Official title: A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-10-15

Completion Date

2030-03-06

Last Updated

2026-03-31

Healthy Volunteers

No

Interventions

DRUG

ALN-5288

ALN-5288 will be administered IT.

DRUG

Placebo

Placebo will be administered IT.

Locations (6)

Clinical Trial Site

Montreal, Canada

Clinical Trial Site

Ottawa, Canada

Clinical Trial Site

Toronto, Canada

Clinical Trial Site

Toronto, Canada

Clinical Trial Site

Glasgow, United Kingdom

Clinical Trial Site

London, United Kingdom